Who Owns Gilenya?

Gilenya's sustainability practices fall under Novartis's global ESG framework.

• Net-Zero Target: Novartis aims to become a net-zero company by 2040. Gilenya's manufacturing processes incorporate energy efficiency measures and waste reduction programs.
• Supply Chain Sustainability: Novartis integrates environmental sustainability criteria in supply contracts. The company introduced the Environmental Sustainability Supplier Playbook in 2023 to guide supplier environmental performance.
• Pharmaceuticals in the Environment (PiE): Novartis conducts environmental risk assessments for its pharmaceutical products, including Gilenya, to assess potential impact on aquatic ecosystems.
• Ethical Clinical Research: Gilenya was developed through Novartis's clinical research framework, which includes independent ethics committee review, patient safety monitoring, and publication of all trial results.
• Patient Access Programs: Novartis implements patient access programs for Gilenya in low- and middle-income countries, including tiered pricing and access partnerships.

Novartis publishes annual ESG reports covering Gilenya's environmental and social performance. Brand-level data for Gilenya is not published separately.

Gilenya has not received formal industry awards. The drug's recognition comes from its clinical significance as the first oral MS therapy.

• First Oral Disease-Modifying Therapy for MS (2010): Gilenya's FDA approval on September 21, 2010, as the first oral disease-modifying therapy for relapsing-remitting MS was recognized as a major advancement in MS treatment by neurologists and MS specialists.
• TRANSFORMS and FREEDOMS Clinical Trials: The pivotal clinical trials that led to Gilenya's approval have been cited extensively in medical literature and presented at major neurology conferences, including the American Academy of Neurology annual meeting.
• Treatment Guideline Inclusion: Gilenya has been included in major MS treatment guidelines, including those from the American Academy of Neurology and the National Multiple Sclerosis Society, reflecting the medical community's recognition of its therapeutic value.
• Over 300,000 Patients Treated: Since its launch, Gilenya has been used by over 300,000 patients in more than 90 countries, representing a significant contribution to MS treatment worldwide.

Gilenya has faced several regulatory challenges and safety concerns throughout its market history.

• FDA Warning on Disease Worsening After Discontinuation (November 2018): The FDA issued a safety warning about severe worsening of multiple sclerosis after stopping Gilenya treatment. The disease can become much worse than before treatment began, potentially resulting in permanent disability. The FDA required a new warning on the Gilenya drug label and patient Medication Guide.
• Cardiovascular Safety Concerns: Gilenya can cause bradycardia (slow heart rate) and heart block after the first dose. The FDA implemented a Risk Evaluation and Mitigation Strategy (REMS) program requiring cardiovascular monitoring for at least six hours after the first dose.
• Infection Risk: Clinical trials identified increased risk of infections, particularly herpetic infections. Two patient deaths were reported in controlled trials due to disseminated herpes zoster and herpes simplex encephalitis. The FDA label includes warnings about herpetic infections.
• Macular Edema Risk: Gilenya is associated with risk of macular edema (fluid accumulation in the retina), requiring regular ophthalmological monitoring for patients with diabetes or history of uveitis.
• Liver Function Monitoring: The medication can cause increases in liver enzymes, requiring regular monitoring of liver function during treatment.
• Pregnancy Contraindication: Gilenya carries contraindications for use during pregnancy due to potential fetal harm. Patients of childbearing potential must use contraception during treatment and for two months after discontinuation.
• Patent Disputes and Generic Entry: Novartis engaged in significant patent litigation to protect Gilenya from generic competition. A 2017 intellectual property rights decision temporarily extended market protection. However, key patents expired, and generic fingolimod entered the US market in 2024, causing a sharp decline in branded revenue.
• Generic Quality Concerns (2024): Clinical reports emerged concerning subpotent generic fingolimod products, with case series documenting clinical and radiological implications of reduced potency in some generic formulations. These concerns raised questions about generic drug quality and bioequivalence in the MS treatment market.